Sex differences in the effects of a combined behavioral and pharmacological treatment strategy for cocaine relapse prevention in an animal model of cue exposure therapy.


Journal

Behavioural brain research
ISSN: 1872-7549
Titre abrégé: Behav Brain Res
Pays: Netherlands
ID NLM: 8004872

Informations de publication

Date de publication:
01 10 2020
Historique:
received: 27 04 2020
revised: 05 07 2020
accepted: 26 07 2020
pubmed: 5 8 2020
medline: 14 10 2021
entrez: 5 8 2020
Statut: ppublish

Résumé

Brief interventions of environmental enrichment (EE) or the glycine transporter-1 inhibitor Org24598 administered with cocaine-cue extinction training were shown previously to inhibit reacquisition of cocaine self-administration in male rats trained to self-administer a moderate 0.3 mg/kg dose of cocaine. Determining how EE and Org24598 synergize in combination in an animal model of cue exposure therapy is novel. Important changes made in this investigation were increasing the cocaine training dose to 1.0 mg/kg and determining sex differences. Adult male and female rats self-administering 1.0 mg/kg cocaine for 35-40 daily sessions exhibited an addiction-like phenotype under a second-order schedule of cocaine delivery and cue presentation. Rats next underwent 6 weekly extinction training sessions for which treatments consisted of EE or NoEE and Vehicle or Org24598 (3.0 mg/kg in males; 3.0 or 7.5 mg/kg in females). Rats then were tested for reacquisition of cocaine self-administration for 15 daily sessions. In males, the combined EE +3.0 mg/kg Org24598 treatment facilitated extinction learning and inhibited reacquisition of cocaine self-administration to a greater extent than no treatment and to individual EE or 3.0 mg/kg Org24598 treatments. In females, EE +7.5 mg/kg Org24598 facilitated extinction learning, but did not inhibit reacquisition of cocaine self-administration. Thus, there were sex differences in the ability of EE + Org24598 administered in conjunction with extinction training to inhibit cocaine relapse in rats exhibiting an addiction-like phenotype. These findings suggest that this multimodal treatment approach might be a feasible option during cue exposure therapy in cocaine-dependent men, but not women.

Identifiants

pubmed: 32750464
pii: S0166-4328(20)30538-6
doi: 10.1016/j.bbr.2020.112839
pmc: PMC7492466
mid: NIHMS1618800
pii:
doi:

Substances chimiques

Cocaine I5Y540LHVR

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112839

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA043454
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Références

Contemp Clin Trials. 2015 Jul;43:223-30
pubmed: 26111923
J Subst Abuse Treat. 2004 Jul;27(1):39-44
pubmed: 15223092
J Psychopharmacol. 1998;12(1):15-22
pubmed: 9584964
J Psychopharmacol. 2019 Mar;33(3):372-382
pubmed: 30644313
J Pharmacol Exp Ther. 2007 Sep;322(3):1103-9
pubmed: 17601982
Nature. 1987 Mar 26-Apr 1;326(6111):338
pubmed: 3031504
Behav Brain Res. 2015 Feb 1;278:462-9
pubmed: 25446811
Behav Brain Res. 2020 May 27;386:112596
pubmed: 32194188
Psychopharmacology (Berl). 2014 Dec;231(24):4585-94
pubmed: 24847958
J Neurosci. 2017 Jul 26;37(30):7198-7208
pubmed: 28659281
Psychopharmacology (Berl). 2010 Apr;209(3):263-70
pubmed: 20198471
Am J Psychiatry. 2005 Aug;162(8):1414-22
pubmed: 16055762
Synapse. 2011 Sep;65(9):938-44
pubmed: 21360592
Neurobiol Learn Mem. 2009 Oct;92(3):381-90
pubmed: 19450699
Annu Rev Clin Psychol. 2007;3:257-84
pubmed: 17716056
Cold Spring Harb Perspect Med. 2013 Apr 01;3(4):a011932
pubmed: 23249442
Neuropsychopharmacology. 2014 Nov;39(12):2742-9
pubmed: 24487737
Pharmacol Biochem Behav. 2017 Jul;158:49-56
pubmed: 28601602
Psychopharmacology (Berl). 2018 Mar;235(3):837-848
pubmed: 29197981
Am J Drug Alcohol Abuse. 2012 Jan;38(1):101-7
pubmed: 21851195
Behav Brain Res. 2018 Apr 2;341:109-113
pubmed: 29288750
Neurobiol Learn Mem. 2010 Jan;93(1):31-6
pubmed: 19666130
J Neurosci. 2019 Apr 10;39(15):2792-2809
pubmed: 30728170
Biol Psychiatry. 2010 Jan 1;67(1):28-35
pubmed: 19709647
Psychopharmacology (Berl). 2011 Jul;216(1):53-62
pubmed: 21308466
Psychopharmacology (Berl). 2005 May;179(3):644-51
pubmed: 15650844
Neuroscience. 2015 Aug 20;301:363-74
pubmed: 26071959
Mol Neurobiol. 2020 May;57(5):2144-2166
pubmed: 31960362
Neurobiol Learn Mem. 2011 Sep;96(2):218-29
pubmed: 21596148
Neurosci Lett. 1989 Mar 13;98(1):91-5
pubmed: 2540460
Am J Drug Alcohol Abuse. 2009;35(6):434-8
pubmed: 20014913
Addiction. 2002 Feb;97(2):155-67
pubmed: 11860387
Front Neural Circuits. 2013 Oct 18;7:149
pubmed: 24151456
Psychopharmacology (Berl). 2000 Feb;148(2):196-200
pubmed: 10663435
Neuropharmacology. 2012 Sep;63(4):635-41
pubmed: 22634364
Biol Psychiatry. 2009 May 15;65(10):851-6
pubmed: 19181308
Neuroreport. 2005 Jan 19;16(1):63-7
pubmed: 15618892
Nat Rev Neurosci. 2000 Dec;1(3):191-8
pubmed: 11257907
Addict Biol. 2017 Jan;22(1):152-162
pubmed: 26384129
Biol Psychiatry. 2016 Aug 15;80(4):274-283
pubmed: 26520240
Am J Addict. 2015 Apr;24(3):217-224
pubmed: 25808169
Neuroscience. 2010 Sep 1;169(3):1127-35
pubmed: 20541592
Nat Commun. 2015 Jul 14;6:7675
pubmed: 26169171
Addict Behav. 1994 May-Jun;19(3):319-31
pubmed: 7942249
Drug Alcohol Depend. 2012 Apr 1;122(1-2):119-26
pubmed: 21992874
Front Behav Neurosci. 2019 Jul 31;13:168
pubmed: 31417375
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15730-4
pubmed: 9861038
Eur J Neurosci. 2013 Jan;37(2):269-77
pubmed: 23106490
Behav Pharmacol. 2009 Jul;20(4):312-21
pubmed: 19584714
Psychopharmacology (Berl). 2015 Mar;232(6):1049-59
pubmed: 25258161
Mol Pharmacol. 2009 Aug;76(2):369-78
pubmed: 19411609
Eur J Pharmacol. 2012 Jun 15;685(1-3):59-69
pubmed: 22542656
J Clin Psychiatry. 2008 Apr;69(4):621-32
pubmed: 18363421
Neuropsychopharmacology. 2009 Dec;34(13):2767-78
pubmed: 19741591
Prog Neurobiol. 2004 Feb;72(3):167-82
pubmed: 15130708
Eur Neuropsychopharmacol. 2019 Jan;29(1):1-15
pubmed: 30497839
eNeuro. 2018 Oct 30;5(5):
pubmed: 30406188
J Vis Exp. 2018 Jun 18;(136):
pubmed: 29985329
Psychopharmacology (Berl). 2005 May;179(3):662-72
pubmed: 15682307
PLoS One. 2011 Feb 23;6(2):e16573
pubmed: 21373180
Pharmacol Biochem Behav. 2018 Mar;166:35-41
pubmed: 29407873
Behav Neurosci. 2003 Apr;117(2):341-9
pubmed: 12708530
Psychopharmacology (Berl). 2011 Jul;216(1):121-9
pubmed: 21318564
Pharmacol Biochem Behav. 2011 Jan;97(3):595-602
pubmed: 20869391
Exp Clin Psychopharmacol. 2007 Feb;15(1):37-47
pubmed: 17295583
Cogn Behav Ther. 2019 Jan;48(1):65-76
pubmed: 30111253
Behav Neurosci. 2006 Oct;120(5):1159-62
pubmed: 17014266
J Subst Abuse Treat. 2013 Aug;45(2):163-72
pubmed: 23561331
Drug Alcohol Depend. 2009 Oct 1;104(3):220-7
pubmed: 19592176
Psychopharmacology (Berl). 2007 Apr;191(2):341-51
pubmed: 17225167
Drug Alcohol Depend. 2019 Dec 1;205:107648
pubmed: 31677490
Biol Sex Differ. 2011 Mar 11;2:3
pubmed: 21396095
Science. 2004 Aug 13;305(5686):1014-7
pubmed: 15310906
Drug Alcohol Depend. 2005 May 9;78(2):211-9
pubmed: 15845325
Behav Pharmacol. 2012 Feb;23(1):43-53
pubmed: 22157144
Psychopharmacology (Berl). 2014 Sep;231(18):3787-98
pubmed: 24595506
Neuroscience. 2012 Sep 18;220:267-76
pubmed: 22710068
Science. 2012 Apr 13;336(6078):241-5
pubmed: 22499948
Psychopharmacology (Berl). 2013 Apr;226(4):739-46
pubmed: 22234379
Am J Psychiatry. 1999 Jan;156(1):11-8
pubmed: 9892292
Neuropsychopharmacology. 2010 Jan;35(2):357-67
pubmed: 19741593
Behav Pharmacol. 2011 Aug;22(4):347-53
pubmed: 21673566
Pharmacol Biochem Behav. 2016 Jun;145:17-23
pubmed: 27003832
Prog Neurobiol. 2009 Dec;89(4):369-82
pubmed: 19819293
Neuropsychopharmacology. 2012 Dec;37(13):2837-45
pubmed: 22948980
Learn Behav. 2016 Sep;44(3):227-38
pubmed: 26511132
Psychopharmacology (Berl). 2014 Feb;231(3):511-9
pubmed: 24051602
Transl Psychiatry. 2015 Apr 07;5:e544
pubmed: 25849983
Addict Biol. 2019 Jan;24(1):65-75
pubmed: 29178664
Psychopharmacology (Berl). 2011 Feb;213(4):817-29
pubmed: 20972552
Neuropsychopharmacology. 2014 Apr;39(5):1059-65
pubmed: 24257156

Auteurs

Kathleen M Kantak (KM)

Department of Psychological and Brain Sciences, Boston University, Boston, USA; Center for Systems Neuroscience, Boston University, Boston, USA. Electronic address: kkantak@bu.edu.

Jamie M Gauthier (JM)

Department of Psychological and Brain Sciences, Boston University, Boston, USA.

Elon Mathieson (E)

Department of Psychological and Brain Sciences, Boston University, Boston, USA.

Eudokia Knyazhanskaya (E)

Department of Psychological and Brain Sciences, Boston University, Boston, USA.

Pedro Rodriguez-Echemendia (P)

Department of Psychological and Brain Sciences, Boston University, Boston, USA.

Heng-Ye Man (HY)

Department of Biology, Boston University, Boston, USA; Center for Systems Neuroscience, Boston University, Boston, USA.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH